Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Upadacitinib Oral Product
Upadacitinib Product · 1 trial · 1 indication
The primary objective of this study is to evaluate whether treatment success in ASUC patients in patients treated with strategy U is non-inferior to strategy C after 16 weeks of initiating therapeutic management.
| Arm | Type | Description |
|---|---|---|
| Upadacitinib (treatment arm) | ACTIVE_COMPARATOR | Participants will receive Upadacitinib 45mg daily, once a day, for at least five days. |
| Infliximab (standard care) | NO_INTERVENTION | Participants will receive standard care, which is Infliximab. |
| Name | Type | Description |
|---|---|---|
| Upadacitinib Oral Product | DRUG | Upadacitinib oral 45mg once daily. |
Inclusion Criteria: Adult (≥ 18 - 64 years) male or non-pregnant, non-lactating female patients with: * Confirmed diagnosis of UC, based on conventional clinical, endoscopic, and/or histologic criteria * Admitted to hospital with acute severe flare and refractory to three days of intravenous steroi...
Upadacitinib Product is an investigational small molecule being studied for the treatment of ulcerative colitis, specifically in patients with steroid-refractory acute severe ulcerative colitis. It is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
Upadacitinib Product is a kinase inhibitor, belonging to the -tinib class of drugs. It works by inhibiting kinase enzymes, which play a role in inflammatory signaling pathways. This mechanism is being evaluated in the context of ulcerative colitis to reduce inflammation and disease activity.
Upadacitinib Product is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The company is conducting clinical trials to evaluate the drug's safety and efficacy in ulcerative colitis.
Upadacitinib Product is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 3 trial is actively recruiting patients to assess its effects in ulcerative colitis.
Upadacitinib Product is being studied in a Phase 3 clinical trial with the identifier NCT06660693. This trial, titled 'Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis,' is recruiting 134 participants in Canada. The study is randomized and active-controlled, and it is currently in the recruiting stage.
Yes, Upadacitinib Product is also known as Upadacitinib Oral Product. Both names refer to the same investigational drug being developed by AbbVie for ulcerative colitis. The oral formulation is the subject of the ongoing Phase 3 clinical trial.